Bharat Biotech and Ocugen To Co-Develop COVAXIN For U.S. Market

US-based biopharmaceutical firm Ocugen Inc and Bharat Biotech on Tuesday anunced that y will co-develop latter's COVID-19 vaccine candidate, COVAXIN, for United States' market. y have signed a binding letter of intent to co-develop vaccine. It is currently undergoing Phase 3 clinical trials in India.

RE | Dr. Fauci Receives Newest COVID-19 Vaccine

Bharat Biotech and Ocugen join hands to develop COVAXIN

"We are delighted to collaborate with Bharat Biotech to potentially bring Covaxin to US market. In face of coronavirus pandemic, it is incumbent upon all of us to find solutions that have potential to save lives and restore rmalcy to our day-to-day activities. We have been very pleased with safety and immugenicity demonstrated by Phase 1 and Phase 2 trials of Covaxin and are encourd with progress of Phase 3 trials in India," said Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen.

RE | 'Crime Will Increase': Interpol Warns Against Attacks On COVID-19 Vaccine Shipment

'Will finalize details of agreement in a few weeks'

two companies (Ocugen Inc and Bharat Biotech) said in a joint statement that y have begun collaborating and will finalize details of definitive agreement in next few weeks. This collaboration levers Ocugen's vaccine expertise, and its R&D and regulatory capabilities in US. As per letter of intent (LOI), "Ocugen will have US rights to vaccine candidate and, in collaboration with Bharat Biotech, will be responsible for clinical development, registration, and commercialization for US market."

y also mention in ir statement that in preparation for development of Covaxin in United States, Ocugen has assembled a Vaccine Scientific visory Board featuring leing acemic and industry experts to evaluate clinical and regulatory path to approval in U.S. market.

RE | US Congresswoman AOC Gets COVID-19 Vaccine On Instagram Live, Documents Entire Process

'We are excited to collaborate with Ocugen'

" development and clinical evaluation of Covaxin marks a significant milestone for vaccilogy in India. Covaxin has garnered interest from several countries worldwide for supplies and introduction and we are excited to collaborate with Ocugen to bring it to US market," Bharat Biotech Chairman and MD Krishna Ella said.

RE | US Official Urges Trump To Get COVID-19 Vaccine To 'generate More Confidence' In Public

(With ncy Inputs)